Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.

[1]  A. Falsey,et al.  Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults. , 2023, The New England journal of medicine.

[2]  M. Boukhvalova,et al.  Human Metapneumovirus (hMPV) Infection and MPV467 Treatment in Immunocompromised Cotton Rats Sigmodon hispidus , 2023, Viruses.

[3]  M. Ison,et al.  LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA) , 2022, Open Forum Infectious Diseases.

[4]  S. Lapp,et al.  An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice , 2022, The Journal of infectious diseases.

[5]  L. Walker,et al.  Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. , 2022, Immunity.

[6]  E. Kerwin,et al.  Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial , 2022, The Journal of infectious diseases.

[7]  Yvonne Wollmann,et al.  A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection , 2022, Frontiers in Immunology.

[8]  J. McLellan,et al.  Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Su,et al.  Profiling of hMPV F-specific antibodies isolated from human memory B cells , 2022, Nature Communications.

[10]  P. Dormitzer,et al.  Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. , 2022, The New England journal of medicine.

[11]  J. McLellan,et al.  Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins , 2022, Nature Communications.

[12]  J. Mousa,et al.  A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein , 2022, bioRxiv.

[13]  Daniel S Spellman,et al.  Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis , 2021, EBioMedicine.

[14]  D. Apter,et al.  Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women , 2021, The Journal of infectious diseases.

[15]  J. Mascola,et al.  Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. , 2021, The Lancet. Respiratory medicine.

[16]  M. Bottomley,et al.  Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein , 2021, mAbs.

[17]  A. Hawes,et al.  Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Madhi,et al.  Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. , 2020, The New England journal of medicine.

[19]  J. Mousa,et al.  Antibody recognition of the Pneumovirus fusion protein trimer interface , 2020, bioRxiv.

[20]  N. Gálvez,et al.  Antibody development for preventing the human respiratory syncytial virus pathology , 2020, Molecular medicine.

[21]  Luciano A. Abriata,et al.  De novo protein design enables the precise induction of RSV-neutralizing antibodies , 2020, Science.

[22]  T. Zaks,et al.  2754. Phase 1 Trial of an mRNA-Based Combination Vaccine Against hMPV and PIV3 , 2019, Open Forum Infectious Diseases.

[23]  H. Su,et al.  A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein , 2019, Nature Communications.

[24]  H. Su,et al.  Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes , 2019, mAbs.

[25]  J. Mascola,et al.  A proof of concept for structure-based vaccine design targeting RSV in humans , 2019, Science.

[26]  R. Tripp,et al.  A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo , 2019, Journal of Virology.

[27]  J. McLellan,et al.  Transient opening of trimeric prefusion RSV F proteins , 2019, Nature Communications.

[28]  P. Piedra,et al.  Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults , 2019, Front. Immunol..

[29]  D. Tabor,et al.  Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015–17 , 2019, Scientific Reports.

[30]  C. Ramos,et al.  Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections , 2019, Haematologica.

[31]  David Baker,et al.  Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus , 2019, Cell.

[32]  John P. Moore,et al.  Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide , 2019, Nature Communications.

[33]  M. Beltramello,et al.  Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4 , 2018, Proceedings of the National Academy of Sciences.

[34]  K. Vora,et al.  1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development , 2018, Open Forum Infectious Diseases.

[35]  H. Lamb,et al.  Palivizumab , 2018, Drugs.

[36]  L. Kauvar,et al.  Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies , 2018, Science Immunology.

[37]  A. Sivasubramanian,et al.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation , 2018, Immunity.

[38]  J. Crowe,et al.  Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins , 2018, PLoS pathogens.

[39]  J. McLellan,et al.  Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses , 2017, EMBO molecular medicine.

[40]  J. McLellan,et al.  Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein , 2017, Nature Communications.

[41]  R. Karron,et al.  Evaluation of a Live Attenuated Human Metapneumovirus Vaccine in Adults and Children , 2017, Journal of the Pediatric Infectious Diseases Society.

[42]  C. Shaw,et al.  Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B , 2017, PloS one.

[43]  J. Crowe,et al.  A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein , 2017, Nature Microbiology.

[44]  O. Ramilo,et al.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. , 2017, Vaccine.

[45]  R. Lamb,et al.  Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus , 2017, Nature Microbiology.

[46]  B. Graham,et al.  A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation , 2016, Nature Communications.

[47]  R. Lamb,et al.  A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV , 2016, PloS one.

[48]  J. V. van Delden,et al.  Respiratory syncytial virus trials and beyond. , 2015, The Lancet. Infectious diseases.

[49]  K. O'Brien,et al.  Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. , 2015, The Lancet. Infectious diseases.

[50]  P. Schultz,et al.  An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold. , 2015, Angewandte Chemie.

[51]  G. Chuang,et al.  Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera , 2015, Science Translational Medicine.

[52]  Peter D. Kwong,et al.  Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions , 2014, Science.

[53]  P. Dormitzer,et al.  A Monomeric Uncleaved Respiratory Syncytial Virus F Antigen Retains Prefusion-Specific Neutralizing Epitopes , 2014, Journal of Virology.

[54]  S. Boyoglu-Barnum,et al.  Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice , 2014, Journal of Virology.

[55]  David Baker,et al.  Proof of principle for epitope-focused vaccine design , 2014, Nature.

[56]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[57]  F. Baldanti,et al.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody , 2013, Nature.

[58]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[59]  Reagan G. Cox,et al.  Breaking In: Human Metapneumovirus Fusion and Entry , 2013, Viruses.

[60]  L. Anderson,et al.  Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice , 2012, PloS one.

[61]  Bernhard Resch,et al.  Burden of respiratory syncytial virus infection in young children. , 2012, World journal of clinical pediatrics.

[62]  Patricia A Jorquera,et al.  Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. , 2012, Viral immunology.

[63]  Jun Chang,et al.  Dual Role of Respiratory Syncytial Virus Glycoprotein Fragment as a Mucosal Immunogen and Chemotactic Adjuvant , 2012, PloS one.

[64]  R. Lamb,et al.  Structure of the Human Metapneumovirus Fusion Protein with Neutralizing Antibody Identifies a Pneumovirus Antigenic Site , 2012, Nature Structural &Molecular Biology.

[65]  A. Osterhaus,et al.  Residues of the Human Metapneumovirus Fusion (F) Protein Critical for Its Strain-Related Fusion Phenotype: Implications for the Virus Replication Cycle , 2011, Journal of Virology.

[66]  W. Schief,et al.  Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. , 2011, Journal of molecular biology.

[67]  P. Kwong,et al.  Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes , 2011, Journal of Virology.

[68]  P. Kwong,et al.  Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F , 2010, Journal of Virology.

[69]  P. Gómez-Puertas,et al.  Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion Glycoprotein , 2010, Journal of Virology.

[70]  Joyce E. Johnson,et al.  Soluble recombinant human metapneumovirus G protein is immunogenic but not protective. , 2010, Vaccine.

[71]  Herren Wu,et al.  Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion , 2010, Journal of Virology.

[72]  P. Kwong,et al.  Structural basis of respiratory syncytial virus neutralization by motavizumab , 2010, Nature Structural &Molecular Biology.

[73]  Oya Cingoz.  Motavizumab , 2009, mAbs.

[74]  M. Takeda,et al.  Efficient Multiplication of Human Metapneumovirus in Vero Cells Expressing the Transmembrane Serine Protease TMPRSS2 , 2008, Journal of Virology.

[75]  T. Heikkinen,et al.  Human Metapneumovirus Infections in Children , 2008, Emerging infectious diseases.

[76]  D. Dimitrov,et al.  Structure and Function of the HIV Envelope Glycoprotein as Entry Mediator, Vaccine Immunogen, and Target for Inhibitors , 2007, Advances in Pharmacology.

[77]  Stacy E. Smith,et al.  Characterization of Human Metapneumovirus F Protein-Promoted Membrane Fusion: Critical Roles for Proteolytic Processing and Low pH , 2006, Journal of Virology.

[78]  J. Kahn.  Epidemiology of Human Metapneumovirus , 2006, Clinical Microbiology Reviews.

[79]  A. Osterhaus,et al.  Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. , 2001, The Journal of infectious diseases.

[80]  M. Peeples,et al.  Functional Analysis of Recombinant Respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene , 2001, Journal of Virology.

[81]  T. Kuiken,et al.  A newly discovered human pneumovirus isolated from young children with respiratory tract disease , 2001, Nature Medicine.

[82]  M. Uhlén,et al.  Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. , 1997, Virology.

[83]  J. Melero,et al.  Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. , 1992, The Journal of general virology.

[84]  J. Hierholzer,et al.  Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay , 1986, Journal of clinical microbiology.

[85]  R. Chanock,et al.  Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. , 1957, American journal of hygiene.

[86]  OUP accepted manuscript , 2021, The Journal of Infectious Diseases.

[87]  Z. Chen,et al.  Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Ef fi cacy Against Both Human Metapneumovirus and Respiratory Syncytial Virus , 2014 .

[88]  J. McLellan,et al.  Structure and function of respiratory syncytial virus surface glycoproteins. , 2013, Current topics in microbiology and immunology.